Therefore, we conducted this retrospective study to investigate the survival benefits and safety profile of afatinib plus ramucirumab in patients with treatment-naïve, EGFR-mutated metastatic, NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.